Up-regulation of Pro-apoptotic Protein Bim and Down-regulation of Anti-apoptotic Protein Mcl-1 Cooperatively Mediate Enhanced Tumor Cell Death Induced by the Combination of ERK Kinase (MEK) Inhibitor and Microtubule Inhibitor
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, the induction of BIM proteins by MEK/ERK inhibition (15, 16) can result in BIM being bound and inhibited by anti-apoptotic BCL-2 and/or BCL-XL, which are frequently overexpressed in solid tumors (17).”
From The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism (2015) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maurer, U., Charvet, C., Wagman, A. S., Dejardin, E., & Green, D. R. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.02.009 · Cited by 881 · cited 1×
“Phosphorylation of Mcl-1 at multiple sites by several kinases contributes to regulation of its stability (34, 35).”
BackgroundGascoigne, K. E., & Taylor, S. S. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.07.002 · Cited by 832 · cited 1×
“Tumor cells manifest marked intraline variation after prolonged exposure to antimitotic agents (25).”
BackgroundLuciano, F., Jacquel, A., Colosetti, P., Herrant, M., Cagnol, S., Pages, G., & Auberger, P. (2003) · Oncogene · doi:10.1038/sj.onc.1206792 · Cited by 477
Domina, A. M., Vrana, J. A., Gregory, M. A., Hann, S. R., & Craig, R. W. (2004) · Oncogene · doi:10.1038/sj.onc.1207692 · Cited by 327 · cited 3×
“PD0325901 induced dephosphorylation and subsequent accumulation of the pro-apoptotic protein BimEL (32) and elicited a slight down-regulation of the prosurvival protein Mcl-1 (17) in the cells (Fig.”
Background
Research works printed but not linked: 36
- Oka, H., Chatani, Y., Hoshino, R., Ogawa, O., Kakehi, Y., Terachi, T., Okada, Y., Kawaichi, M., Kohno, M., and Yoshida, O. (1995) Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res. 55, 4182-4187
- Hoshino, R., Chatani, Y., Yamori, T., Tsuruo, T., Oka, H., Yoshida, O., Shimada, Y., Ari-i, S., Wada, H., Fujimoto, J., and Kohno, M. (1999) Con- stitutive activation of the 41/43-kDa mitogen-activated protein kinase sig- naling pathway in human tumors. Oncogene 18, 813-822 · DOI · Paper page
- Hynes, N. E., and Lane, H. A. (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 5, 341-354 · DOI · Paper page
- Downward, J. (2003) Targeting RAS signaling pathways in cancer therapy. Nat. Rev. Cancer 3, 11-22 · DOI · Paper page
- Wellbrock, C., Karasarides, M., and Marais, R. (2004) The RAF proteins take center stage. Nat. Rev. Mol. Cell Biol. 5, 875-885 · DOI · Paper page
- Lewis, T. S., Shapiro, P. S., and Ahn, N. G. (1998) Signal transduction through MAP kinase cascades. Adv. Cancer Res. 74, 49 -139 · DOI · Paper page
- Sebolt-Leopold, J. S., and Herrera, R. (2004) Targeting the mitogen-acti- vated protein kinase cascade to treat cancer. Nat. Rev. Cancer 4, 937-947 · DOI · Paper page
- Kohno, M., and Pouyssegur, J. (2006) Targeting the ERK signaling path- way in cancer therapy. Ann. Med. 38, 200 -211 · DOI · Paper page
- Hoshino, R., Tanimura, S., Watanabe, K., Kataoka, T., and Kohno, M. (2001) Blockade of the extracellular signal-regulated kinase pathway in- duces marked G 1 cell cycle arrest and apoptosis in tumor cells in which the pathway is constitutively activated: up-regulation of p27 Kip1 . J. Biol. Chem. 276, 2686 -2692 · DOI · Paper page
- Tanimura, S., Asato, K., Fujishiro, S. H., and Kohno, M. (2003) Specific blockade of the ERK pathway inhibits the invasiveness of tumor cells: down-regulation of matrix metalloproteinase-3/9/14 and CD44. Biochem. Biophys. Res. Commun. 304, 801-806 · DOI
- Tanimura, S., Uchiyama, A., Watanabe, K., Yasunaga, M., Inada, Y., Kawa- bata, T., Iwashita, K., Noda, S., Ozaki, K., and Kohno, M. (2009) Blockade of constitutively activated ERK signaling enhances cytotoxicity of micro- tubule-destabilizing agents in tumor cells. Biochem. Biophys. Res. Com- mun. 378, 650 -655 · doi:10.1016/j.bbrc.2008.11.109
- Yeh, T. C., Marsh, V., Bernat, B. A., Ballard, J., Colwell, H., Evans, R. J., Parry, J., Smith, D., Brandhuber, B. J., Gross, S., Marlow, A., Hurley, B., Lyssikatos, J., Lee, P. A., Winkler, J. D., Koch, K., and Wallace, E. (2007) Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin. Can- cer Res. 13, 1576 -1583 · DOI · Paper page
- Rinehart, J., Adjei, A. A., Lorusso, P. M., Waterhouse, D., Hecht, J. R., Natale, R. B., Hamid, O., Varterasian, M., Asbury, P., Kaldjian, E. P., Gu- lyas, S., Mitchell, D. Y., Herrera, R., Sebolt-Leopold, J. S., and Meyer, M. B. (2004) Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small cell lung, breast, colon, and pancreatic cancer. J. Clin. Oncol. 22, 4456 -4462 · DOI · Paper page
- Adjei, A. A., Cohen, R. B., Franklin, W., Morris, C., Wilson, D., Molina, J. R., Hanson, L. J., Gore, L., Chow, L., Leong, S., Maloney, L., Gordon, G., Simmons, H., Marlow, A., Litwiler, K., Brown, S., Poch, G., Kane, K., Haney, J., and Eckhardt, S. G. (2008) Phase I pharmacokinetic and phar- macodynamic study of the oral, small-molecule mitogen-activated pro- tein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J. Clin. Oncol. 26, 2139 -2146 · DOI · Paper page
- Youle, R. J., and Strasser, A. (2008) The Bcl-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 9, 47-59 · DOI · Paper page
- MacKeigan, J. P., Collins, T. S., and Ting, J. P. (2000) MEK inhibition enhances paclitaxel-induced tumor apoptosis. J. Biol. Chem. 275, 38953-38956 · DOI · Paper page
- McDaid, H. M., Lopez-Barcons, L., Grossman, A., Lia, M., Keller, S., Pérez- Soler, R., and Horwitz, S. B. (2005) Enhancement of the therapeutic effi- cacy of Taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants. Cancer Res. 65, 2854 -2860 · DOI
- Watanabe, K., Tanimura, S., Uchiyama, A., Sakamoto, T., Kawabata, T., Ozaki, K., and Kohno, M. (2010) Blockade of the extracellular signal- regulated kinase pathway enhances the therapeutic efficacy of microtu- bule-destabilizing agents in human tumor xenograft models. Clin. Cancer Res. 16, 1170 -1178 · DOI
- Musacchio, A., and Salmon, E. D. (2007) The spindle-assembly checkpoint in space and time. Nat. Rev. Mol. Cell Biol. 8, 379 -393 · DOI · Paper page
- Tamemoto, H., Kadowaki, T., Tobe, K., Ueki, K., Izumi, T., Chatani, Y., Kohno, M., Kasuga, M., Yazaki, Y., and Akanuma, Y. (1992) Biphasic ac- tivation of two mitogen-activated protein kinases during the cell cycle in mammalian cells. J. Biol. Chem. 267, 20293-20297 · DOI · Paper page
- Iwasaki, S., Iguchi, M., Watanabe, K., Hoshino, R., Tsujimoto, M., and Kohno, M. (1999) Specific activation of the p38 mitogen-activated protein kinase signaling pathway and induction of neurite outgrowth in PC12 cells by bone morphogenetic protein-2. J. Biol. Chem. 274, 26503-26510 · DOI · Paper page
- Tanimura, S., Hirano, A. I., Hashizume, J., Yasunaga, M., Kawabata, T., Ozaki, K., and Kohno, M. (2007) Anticancer drugs up-regulate HspBP1 and thereby antagonize the prosurvival function of Hsp70 in tumor cells. J. Biol. Chem. 282, 35430 -35439 · DOI
- Rieder, C. L., and Maiato, H. (2004) Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. Dev. Cell 7, 637-651 · DOI · Paper page
- Blagosklonny, M. V. (2007) Mitotic arrest and cell fate: why and how mitotic inhibition of transcription drives mutually exclusive events. Cell Cycle 6, 70 -74 · DOI · Paper page
- Weaver, B. A., and Cleveland, D. W. (2005) Decoding the links between mitosis, cancer, and chemotherapy: the mitotic checkpoint, adaptation, and cell death. Cancer Cell 8, 7-12 · DOI · Paper page
- Kaestner, P., and Bastians, H. (2010) Mitotic drug targets. J. Cell. Biochem. 111, 258 -265 · DOI
- Janssen, A., and Medema, R. H. (2011) Mitosis as an anticancer target. Oncogene 30, 2799 -2809 · DOI
- Hans, F., and Dimitrov, S. (2001) Histone H3 phosphorylation and cell division. Oncogene 20, 3021-3027 · DOI · Paper page
- Blagosklonny, M. V. (2001) Unwinding the loop of Bcl-2 phosphorylation. Leukemia 15, 869 -874 · DOI
- Zhong, Q., Gao, W., Du, F., and Wang, X. (2005) Mule/ARF-BP1, a BH3- only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 121, 1085-1095 · DOI · Paper page
- Harley, M. E., Allan, L. A., Sanderson, H. S., and Clarke, P. R. (2010) Phosphorylation of Mcl-1 by CDK1-cyclin B 1 initiates its Cdc20-depen- dent destruction during mitotic arrest. EMBO J. 29, 2407-2420 · DOI · Paper page
- Nijhawan, D., Fang, M., Traer, E., Zhong, Q., Gao, W., Du, F., and Wang, X. (2003) Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev. 17, 1475-1486 · DOI · Paper page
- Cuconati, A., Mukherjee, C., Perez, D., and White, E. (2003) DNA damage response and MCL-1 destruction initiate apoptosis in adenovirus-infected cells. Genes Dev. 17, 2922-2932 · DOI · Paper page
- Jackson, J. R., Patrick, D. R., Dar, M. M., and Huang, P. S. (2007) Targeted antimitotic therapies: can we improve on tubulin agents? Nat. Rev. Cancer 7, 107-117 · DOI · Paper page
- Fennell, D. A., Chacko, A., and Mutti, L. (2008) Bcl-2 family regulation by the 20 S proteasome inhibitor bortezomib. Oncogene 27, 1189 -1197 · DOI
- Kohno, M., Tanimura, S., and Ozaki, K. (2011) Targeting the extracellular signal-regulated kinase pathway in cancer therapy. Biol. Pharm. Bull. 34, 1781-1784 · DOI
Cited by
Zaanan, A., Okamoto, K., Kawakami, H., Khazaie, K., Huang, S., & Sinicrope, F. A. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.657833 · Cited by 59
“However, the induction of BIM proteins by MEK/ERK inhibition (15, 16) can result in BIM being bound and inhibited by anti-apoptotic BCL-2 and/or BCL-XL, which are frequently overexpressed in solid tumors (17).”
Background
Metadata
- Authors
- Kawabata, T., Tanimura, S., Asai, K., Kawasaki, R., Matsumaru, Y., & Kohno, M.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2012-03
- Volume
- 287
- Issue
- 13
- Pages
- 10289-10300
- ISSN
- 0021-9258
- Cited by
- 22
- References
- 4
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 3123 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.